Raymond James Financial
RGC icon

Raymond James Financial’s Regencell Bioscience RGC Stock Holding History

Raymond James Financial’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-71
Closed -$1.21K – 6378
2025
Q2 		$1.21K Buy
+71
New +$866 ﹤0.01% 6525

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James Financial's RGC Position: Q3 2025 in Review

Raymond James Financial sold out of Regencell Bioscience (RGC) in Q3 2025, closing a stake of 71 shares — an estimated $1.21K sold.

Raymond James Financial first reported a position in RGC in Q2 2025 and held it in 1 quarter. The position peaked at $1.21K in Q2 2025. 16 funds tracked by Wall St. Rank hold RGC as of Q3 2025.

  • Raymond James Financial reported no remaining Regencell Bioscience position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 71 Regencell Bioscience shares in Q3 2025, an estimated $1.21K.
  • Raymond James Financial first reported a position in Regencell Bioscience in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Regencell Bioscience position peaked at $1.21K in Q2 2025.
  • 16 funds tracked by Wall St. Rank held Regencell Bioscience as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.